12 results on '"Weisel K"'
Search Results
2. Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma
3. Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma
4. ABO-INCOMPATIBLE RED BLOOD CELL TRANSFUSION: SUCCESSFUL USE OF ECULIZUMAB FOR TREATMENT OF THE ACUTE HEMOLYTIC REACTION: 3D-S20-04
5. Bortezomib Desensitization in Kidney Transplantation — Effect on HLA-Antibody Titers and Adaptive Immunity.: Abstract# 690: Poster Board #-Session: P158-I
6. Bortezomib before and after high-dose chemotherapy improves the survival in patients with newly diagnosed multiple myeloma and renal insufficiency - a subgroup analysis of the prospective randomised GMMG HD4/HOVON 65 study: V817
7. Bortezomib during induction and maintenance before and after autologous transplantation improves overall survival in patients with renal impairment: subgroup analysis from the HOVON-65/GMMG-HD4 randomized trial for newly diagnosed multiple myeloma: O270
8. Treatment of multiple myeloma patients with renal disease: V39
9. Topoisomerase-based chemotherapy in adults with relapsed or refractory pediatric-type sarcoma: PO426
10. Bortezomib, iv cyclophosphamide and dexamethasone (VCD) as induction therapy in newly diagnosed multiple myeloma: Update on the interim results with 300 patients of the German DSMM XIa trial: V333 - Best Abstract
11. Contamination of autologous peripheral blood progenitor cell grafts predicts overall survival after high-dose chemotherapy in multiple myeloma
12. Overexpression of wnt-1 in embryonic stem cells blocks hematopoietic differentiation and promotes cardiomyogenesis: V149
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.